Has Brian Hogan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $123,460 in general payments to Brian Hogan, MD across 1,508 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Brian Hogan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Brian Hogan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Brian Hogan, MD

Neurology · Tuscaloosa, ALNPI 1679677298

Payments from drug & device makers

$123,460in general payments, 2019–2025

Across 1,508 payments — averaging $81.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$26K
Amgen$24K
Biohaven Pharmaceutical Holding Company Ltd.$21K
Biohaven Pharmaceuticals, Inc.$20K
Teva Pharmaceuticals USA, Inc.$13K
UCB, Inc.$3K
plus $17K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	263	$25,602
Amgen(2 entities)	81	$24,332
Biohaven Pharmaceutical Holding Company Ltd.	34	$20,501
Biohaven Pharmaceuticals, Inc.	40	$20,047
Teva Pharmaceuticals USA, Inc.	94	$12,603
UCB, Inc.	69	$2,908
Biogen	108	$1,708
Pfizer	99	$1,204
CSL Behring	28	$1,003
Novartis	49	$822
Neurocrine Biosciences, Inc.	37	$710
Eisai Inc.	25	$681
AstraZeneca(2 entities)	30	$641
Genentech USA, Inc.	28	$599
SK Life Science, Inc.	26	$570
Lilly USA, LLC	32	$485
Lundbeck LLC	23	$471
Acadia Pharmaceuticals Inc	26	$457
Otsuka America Pharmaceutical, Inc.	29	$453
Grifols USA, LLC	22	$430
Catalyst Pharmaceuticals, Inc.	20	$415
Argenx US, Inc.	17	$408
Neurelis, Inc.	25	$375
Merz Pharmaceuticals, LLC	16	$366
Ipsen Biopharmaceuticals, Inc	16	$332
EMD Serono, Inc.	14	$327
Kyowa Kirin, Inc.	16	$311
Upsher-smith Laboratories LLC	15	$304
ANI Pharmaceuticals, Inc.	4	$279
Takeda Pharmaceuticals U.S.A., Inc.	12	$244
Acorda Therapeutics, Inc	13	$231
Sanofi	11	$219
Johnson & Johnson(2 entities)	12	$217
Bristol Myers Squibb	12	$209
Adamas Pharmaceuticals, Inc.	10	$199
Jazz Pharmaceuticals Inc.	10	$192
Tanabe Pharma America, Inc.	9	$182
Greenwich Biosciences, Inc.	10	$173
TG Therapeutics, Inc.	9	$171
Supernus Pharmaceuticals, Inc.	7	$169
Amneal Pharmaceuticals LLC	10	$165
Avanir Pharmaceuticals, Inc.	10	$155
Akcea Therapeutics, Inc.	8	$137
Aucta Pharmaceuticals, Inc.	5	$106
MDD US Operations, LLC	6	$104
Aquestive Therapeutics, Inc.	6	$99
Scilex Pharmaceuticals Inc.	5	$93
Xeris Pharmaceuticals, Inc.	4	$88
Alnylam Pharmaceuticals Inc.	3	$71
Vanda Pharmaceuticals Inc.	3	$67
Averitas Pharma Inc.	3	$66
Impel Pharmaceuticals Inc.	3	$62
Inspire Medical Systems, Inc.	2	$56
Harmony Biosciences LLC	3	$54
Strongbridge US Inc.	4	$53
Axsome Therapeutics, Inc.	3	$47
Zyla Life Sciences, Inc.	3	$47
GE HealthCare	2	$42
Assertio Therapeutics, Inc.	3	$41
Otsuka Pharmaceutical Development & Commercialization, Inc.	2	$36

How this compares

$123,460 in reported general payments places this provider in the 85th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama →

Medicare billing

Part B allowed, 2024

$158,555

Medicare patients

513

Services billed

5,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Tuscaloosa

Timothy PrestleyTuscaloosa$256K
Emily RiserBirmingham$7.1M
Christopher LagankeCullman$5.9M
Louis NaborsBirmingham$3.2M
Belinda Savage-EdwardsHuntsville$2.8M
Khurram BashirBirmingham$2.8M
David GeldmacherBirmingham$2.6M
Victor SungBirmingham$2M
Mina LobbousBirmingham$1.8M
Diane CounceBirmingham$1.4M

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →